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Article Information  ABSTRACT 
Received: 12th October 2020  The aim of present study was to prepared ocular in-situ gel to increase the residence time of drug in 
cornea for improvement of ocular bioavailability of drug. In situ gel of Loteprednol etabonate was 
prepared by using carobopol 940 and different grades of HPMC in different ratios by pH triggered 
method. The prepared in situ gels were evaluated for pH, drug content, viscosity, gelling time, gelling 
strength spreadability and sterility testing. In vitro drug release study was carried by using diffusion 
cell with dialysis membrane. The drug content and pH of the formulation were found to be satisfactory. 
The gelling strength was found to be in the range of 34 seconds to 91 seconds. The viscosity and 
spredability of the formulations were found to be satisfactory. Formulation F5 containing 0.3 % 
carobopol 940 and 0.6 % HPMC K4M showed highest drug release of 80.30 %. The developed 
formulations showed sustained release of drug up to 8 hrs. From in-vitro drug release studies, it could 
be concluded that the developed in-situ gelling systems were thus a better alternative to conventional 
eye drops. 
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INTRODUCTION 
Eye is the most critical organ of the body. The eye ball is cover 
through three layers: an outer fibrous protective layer (sclera and 
cornea), a middle vascular layer (choroid), and an inner nervous 
layer (retina). Eye goes through from a various problems like 
glaucoma, endopthalmitis, dry eye syndrome, trachoma, 
keratitis, conjunctivitis. Therefore, the drug required at ocular 
site in therapeutic dose has been one of the most challenging 
tasks until now [1]. Various factors such as nasolacrimal 
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drainage of drug, binding of drug to lachrymal protein, induced 
lachrymation, availability of limited corneal area generate a 
barrier for absorption of drug through ocular routes [2,3]. The 
conventional ophthalmic drug delivery system in the form of eye 
drops, have a dynamic effect and high tear fluid income that 
causes rapid pre-corneal elimination of the drug and also only 1-
10% of topically applied drug get absorbed that frequently 
results in poor bioavailability and therapeutic response [4]. 
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Various formulations like inserts, ointments, suspensions, and 
aqueous gels, have been developed in order to get longer the 
residence time of instilled dose and improve the ophthalmic 
bioavailability [5].  because of low patient observance in using 
the inserts and the side effect of using an ointment such as 
blurred vision, these ocular drug delivery systems has not been 
used. This new drug delivery systems that have been developed 
established by ophthalmologists is in-situ gel systems. In-situ gel 
forming system have been showed their potential in lengthen the 
residential time because of bio adhesiveness of formed gel that 
have been produced. Additionally, polymers used to achieve in-
situ gelling may result in sustained release of drug molecules.[6-
8] In-situ gelling systems are described as low viscosity solution 
that phase transition in cul-de-sac to form viscoelastic gel. This 
sol-to-gel phase transition happen due to conformational 
changes of polymer in response to a physiological environment. 
In-situ formulations are more suitable for patient because they 
are administered as solution or suspension which immediately 
undergoes to gelation as coming in contact with the eye. 
Loteprednol etabonate is used as an anti-inflammatory agent. It 
belongs to BCS class II drug and half life of 2.8 hours. It has 
very slightly soluble in water, soluble in methanol.  
 
MATERIALS AND METHODS 
Material 
Loteprednol etabonate was obtained as a gift sample from 
Yarrow Chem Product, Mumbai. All other ingredients were used 
of analytical grade. 
 
Formulation of in situ gel 
The in-situ gelling polymer was added slowly in distilled water 
with continuous stirring until completely dissolved. Another 
polymeric solution (carbopol 940 solution) was made and 
allowed to hydrate overnight. After mixing and complete 
hydration of polymers, drug was added to the polymeric 
solution. The resultant solution was thoroughly mixed until 
uniform and clear solution was formed. Final volume was made 
by adding required volume of distilled water. Different grade of 
HPMC used as viscosifying agent and carbopol 940 used as pH 
inducing agent/ gelling agent. 
 
EVALUATION OF IN SITU GEL 
pH of in-situ gel: pH of each formulation was determined by 
using pH meter which was previously calibrated using standard 
buffer of pH 4 and pH 7. pH was measured by taking 1 ml 
formulation which was diluted with simulated tear fluid pH 7.4. 
[9] 
 
Drug content: 1 ml of formulation was taken in 10 ml of 
volumetric flask and at that point diluted with simulated tear 
fluid pH 7.4 up to 10 ml. Yet again 1 ml quantity from this 
solution was taken and diluted with 10 ml of simulated tear fluid 
pH 7.4. Lastly, the absorbance of prepared solution was 
measured at 212 nm against blank reagent using UV visible 
spectrophotometer. [10] 
 
Viscosity measurement: Viscosity of prepared formulation was 
determined using Brookfield  viscometer  with  spindle no. 62 at 
50-100 rpm at temperature 37±0.5 ͦ C. Spindle was lowered 
perpendicularly into gel placed in a beaker taking care that   the 
spindle does not touch the bottom of beaker. Reading were 
recorded after 30 sec. [11] 
 
Gelling time: The gelling time was determined by dropping the 
formulation in a test tube containing 2.0 ml of freshly prepared 
simulated tear fluid pH 7.4 and the gelation was observed by 
visual examination. [12] 
Table I: Formulation composition of in situ gel 
Ingredients F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 
LE* (%) 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 
Carbopol 940 (%) 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 
HPMC K15M (%) 0.4 0.6 0.8 - - - - - - - - - 
HPMC K4M (%) - - - 0.4 0.6 0.8 - - - - - - 
HPMC E15LV (%) - - - - - - 0.4 0.6 0.8 - - - 
HPMC E50LV (%) - - - - - - - - - 0.4 0.6 0.8 
Methyl Paraben (%) 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 
Distilled Water  q.s q.s q.s q.s q.s q.s q.s q.s q.s q.s q.s q.s 
*LE꞊ Loteprednol etabonate 
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Gelling strength: The prepared gel was placed in 100 ml 
measuring cylinder the probe was placed on the gel and a weight 
was placed on the probe. The probe was allowed to penetrate at 
a distance of 5 cm and time required for penetration was noted 
as a gelling strength. [13] 
 
Spreadability: Excess of sample was applied in between 2 glass 
slide and was compressed to uniform thickness by placing 100- 
gram weight over the upper glass slide for 5 minutes. Weight 50 
gram was added to pan. Time required separating the two slides 
i.e. the time in which the upper glass slide move over the lower 





Where, S= Spreadability; m= weight tied to upper slide; t= time 
taken, 1= length moved on upper glass slide 
In vitro drug release: The drug release of the Loteprednol 
etabonate in-situ ophthalmic gel was measured using Franz 
diffusion cell with dialysis membrane (mol. Wt. 12000D) as a 
barrier. Assembly was set and the temperature was maintained 
at 37±0.5°C, then 2 ml of in-situ ophthalmic gel of Loteprednol 
etabonate was filled in the donor compartment, which was 
separated from the receptor compartment with the dialysis 
membrane.  
 
The receptor compartment was filled with the simulated tear 
fluid pH 7.4. 1 ml aliquots of sample were withdrawn at regular 
time intervals and replaced with an equal volume of simulated 
tear fluid pH 7.4 as fresh receptor medium. The samples were 
appropriately diluted with simulated tear fluid pH 7.4 and 
analyzed spectrophotometrically at 212 nm. [15] 
 
 
Table 2: Evaluation parameters of batches F1 -F12 
Batch no. Drug Content (%) pH Gelling Time (sec) Spreadability gcm/sec 
F1 96.67 ± 0.16 6.48±0.18 7.4 ± 0.250 38.62 ± 0.20 
F2 97.51 ± 0.14 6.45±0.11 10.2 ± 1.124 33.33 ± 0.18 
F3 97.28 ± 0.25 6.6±0.24 11 ± 0.062 28.61 ± 0.21 
F4 97.45 ± 0.04 6.75±0.15 8.1 ± 1.413 26.61 ±0.11 
F5 98.80 ± 0.30 6.8±0.05 4.5±0.932 30.42 ± 0.15 
F6 97.77 ± 0.19 6.53±0.12 9.1 ± 0.045 22.46 ± 0.10 
F7 94.49 ± 0.18 6.08±0.1 10 ± 0.206 37.69 ± 0.22 
F8 96.61 ± 0.21 6.55±0.20 7.9 ± 0.120 36.57 ±0.15 
F9 94.35 ± 0.18 6.71±0.09 6.0 ± 0.566 31.52 ± 0.25 
F10 96.46 ± 0.26 6.6±0.24 9.2 ± 1.145 45.55 ± 0.27 
F11 96.21 ± 0.26 6.75±0.15 7.5 ± 0.120 42.55 ± 0.02 
F12 97.01 ± 0.01 6.55±0.20 4.5 ± 0.932 37.62 ± 0.20 
*Each observation values are expressed as mean ±S.D. of n=3 
 
RESULT AND DISCUSSION  
Drug content of all the formulation was establish to be in the 
range of 94.24 to 98.80 %. The loteprednol etabonate content in 
all formulation was almost stable F5 shows highest drug content. 
The drug content was carried out in triplicates.  
 
pH of solution at time of instillation of all formulations was 
found to be in the range of pH 6.08 to 6.80. Spreadability of 
formulation indicates that ease of application of drug. 
Spreadability of all the formulation was found to be in range 
from 26.61 to 45.55 gcm/sec. In all of the above formulations, 
viscosity increases as the polymer concentration increases.  
The viscosity for solution was found in the range of cps 68 to 
225 cps and the viscosity for gel was found to be in the range of 
cps 171 to 430 cps. Gelling strength of the formulation was 
found in the range from 30 sec to 86 sec.  
 
Amongst all these formulations, the maximum drug release was 
found to be 98.41% for F5 and it was also observed that drug 
release decreases by increasing the concentration polymers. 
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Table 3: Evaluation parameters of batches F1 -F12 
Batch 
 
Viscosity (cps) Gelling Strength 
(sec) Solution Gel 
F1 92 ± 0.57 165 ± 0.35 45 ± 0.30 
F2 131 ± 0.57 320 ± 0.18 61 ± 0.19 
F3 157 ± 0.20 341 ± 0.17 72 ± 0.20 
F4 68 ± 0.16 171 ± 0.19 30 ± 0.20 
F5 85 ± 0.21 237 ± 0.01 45 ± 0.30 
F6 103 ± 0.06 325 ± 0.17 66 ± 0.36 
F7 79 ± 0.19 215 ± 0.05 42 ± 0.31 
F8 150 ± 0.25 370 ± 0.07 53 ± 0.21 
F9 225 ± 0.28 430 ± 0.01 59 ± 0.10 
F10 95 ± 0.04 225 ± 0.11 50 ± 0.20 
F11 126 ± 0.07 270 ± 0.07 65 ± 0.30 
F12 143 ± 0.30 342 ± 0.17 86 ± 0.09 
*Each observation values are expressed as mean ±S.D. of n=3 
 
 
Figure 1: In vitro drug released of F1 – F3 
 
Figure 2: In vitro drug released of F4-F6 
 
CONCLUSION 
To overcome reduced corneal permeability of steroid 
cyclodextrin, inclusion complexes was developed. Aqueous 
solubility and corneal perfusion are increased. β-CD, one of the 
natural unsubstituted cyclodextrins, was employed for solubility 
enhancement of the drug. Eight hour in vitro drug release 




Figure 3: In vitro drug released of F7-F9 
 
 
Figure 4: In vitro drug released of F10-F12 
 
FINANCIAL ASSISTANCE  
Nil 
 
CONFLICT OF INTEREST  
The authors declare no conflict of interest. 
 
AUTHOR CONTRIBUTION 
Shaikh shoaeba has conducted the laboratory experiment. Hitesh 
Jain and Asit shahu has designed and guided shaikh shoaeba for 
overall study and in preparing the manuscript. D.B.Meshram 
supervised the overall study and the manuscript. 
 
REFERENCES  
[1] Nalla A, Chinnala KM. In-situ ophthalmic drug delivery 
systems- an overview. Indo American Journal of 







































































Journal of Applied Pharmaceutical Research 9 (2); 2021: 25 – 29   Shaikh et. al  
 
 
  Journal of Applied Pharmaceutical Research (JOAPR)| April – June 2021 | Volume 9 Issue 2 |   29 
[2] Sirisuru P., Parvathi M., Formulation and evaluation of in-
situ gelling system for ocular delivery of timolol maleate. 
International Journal of Pharmaceutical, Chemical and 
Biological Sciences, 3(1), 81-89 (2014). 
[3] Mittal N, Kaur G. In situ gelling ophthalmic drug delivery 
system: formulation and evaluation. Journal of Applied 
Polymer Science, 1-9 (2013). 
[4] Arora K, Singh S. Preparation and evaluation of pH and 
temperature sensitive polymer based in-situ gel for ocular 
delivery. World Journal of Pharmacy and Pharmaceutical 
Sciences, 6 (1), 1366-1381 (2017) 
[5] Gupta C, Juyal V, Nagaich U. Formulation, optimization, 
and evaluation of in-situ gel of moxifloxacin hydrochloride 
for ophthalmic drug delivery. International Journal of 
Applied Pharmaceutics, 11(4), 147-158 (2019) 
[6] Rajoria G and Gupta A. In-situ gelling system: a novel 
approach for ocular drug delivery. American 
Journal of PharmTech Research, 2, 2249-3387 (2012) 
[7] Rathore KS. In-situ gelling ophthalmic drug delivery 
system: an overview. Int J Pharm Sci Res, 2, 30-34 (2010) 
[8] Amaliyar PR and Chaudhary S. In-situ gel forming a novel 
approach for sustained ophthalmic drug delivery. 
International Journal of Pharmaceutical, Chemical and 




















[9] Cao Y et al. Poly (Nisopropylacrylamide)-chitosan as 
thermosensitive in- situ gel-forming system for ocular drug 
delivery. Journal of Controlled Release, 186-194 (2007). 
[10] Patil AP, Tagalpallewar AA and Rasve GM. A novel 
ophthalmic drug delivery systems: in- situ gel. International 
Journal of Pharmaceutical Sciences and Research, 3, 
2938-2946 (2012) 
[11] Pallavi R, Kute SB, Gondkar and Saudagar RB, Ophthalmic 
in-situ gel:  an overview. World Journal of Pharmaceutical 
Research, 4(4), 549-568 (2015) 
[12] Kavitha K and Rajas NJ, Sustained ophthalmic delivery of 
levofloxacin hemihydrate from an ion activated in situ 
gelling system. International Journal of PharmTech 
Research, 3(2), 702-706 (2011) 
[13] Garge L and Saudagar R. Ophthalmic pH sensitive in-situ 
gel: a review. Journal of drug delivery and therapeutics 
9(2), 682-689 (2019) 
[14] Rukari TG, Jadhav AS, Londhe RA and Phalke PL. A 
review on ophthalmic in situ gels. American 
Journal of Pharmtech Research, 9(2), 159-170 (2019) 
[15] Chavan PM and Vyas S. A novel approach in-situ gel for 
sustained drug delivery: a review. International Jounral of 
Pharmceutics, 9(4), 260-280 (2017) 
